The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2017 Oct 3

PMID 28968800

Citations 13

Authors

Melanie Drolet

Jean-Francois Laprise

Julia M L Brotherton

Basil Donovan

Christopher K Fairley

Hammad Ali

Elodie Benard

Dave Martin

Marc Brisson

Affiliations

Soon will be listed here.

Abstract

We used transmission-dynamic modeling to estimate the added effectiveness of vaccinating multiple cohorts of females (12-26 years) in Australia compared with the theoretical introduction of routine-only (12-13 years) vaccination. Our results suggest that vaccinating multiple cohorts produced markedly faster direct/herd effects, and it added benefits that last for 20-70 years. Furthermore, the number needed to vaccinate to prevent 1 anogential warts (AGW) case or cervical cancer (CC) was similar for routine + catch-up (AGW = 9.9, CC = 678) and routine-only vaccination (AGW = 9.9, CC = 677), thus providing similar levels of efficiency per person vaccinated.

Citing Articles

Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling.

Brisson M, Laprise J, Drolet M, Chamberland E, Benard E, Burger E J Natl Cancer Inst Monogr. 2024; 2024(67):387-399.

PMID: 39529531 PMC: 11555275. DOI: 10.1093/jncimonographs/lgae038.

Effectiveness of bivalent HPV vaccination against genital HPV DNA-positivity of a catch-up campaign at age 13-16 years compared to routine vaccination at age 12 years: a biennial repeated cross-sectional study.

Kusters J, Schim van der Loeff M, van Benthem B, King A, de Melker H, Heijman T BMC Med. 2024; 22(1):469.

PMID: 39407233 PMC: 11475922. DOI: 10.1186/s12916-024-03686-4.

Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis.

Drolet M, Laprise J, Chamberland E, Sauvageau C, Wilson S, Lim G CMAJ. 2024; 196(33):E1136-E1143.

PMID: 39374971 PMC: 11464022. DOI: 10.1503/cmaj.240787.

Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening.

Boily M, Barnabas R, Ronn M, Bayer C, van Schalkwyk C, Soni N EClinicalMedicine. 2022; 54:101754.

PMID: 36583170 PMC: 9793279. DOI: 10.1016/j.eclinm.2022.101754.

Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State.

Akhatova A, Azizan A, Atageldiyeva K, Ashimkhanova A, Marat A, Iztleuov Y Vaccines (Basel). 2022; 10(11).

PMID: 36423008 PMC: 9696339. DOI: 10.3390/vaccines10111912.

References

Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch F . Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016; 4(7):e453-63. DOI: 10.1016/S2214-109X(16)30099-7. View

Winer R, Kiviat N, Hughes J, Adam D, Lee S, Kuypers J . Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005; 191(5):731-8. DOI: 10.1086/427557. View

Wellings K, Collumbien M, Slaymaker E, Singh S, Hodges Z, Patel D . Sexual behaviour in context: a global perspective. Lancet. 2006; 368(9548):1706-28. DOI: 10.1016/S0140-6736(06)69479-8. View

Van de Velde N, Boily M, Drolet M, Franco E, Mayrand M, Kliewer E . Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012; 104(22):1712-23. DOI: 10.1093/jnci/djs395. View

Flagg E, Schwartz R, Weinstock H . Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health. 2013; 103(8):1428-35. PMC: 4007878. DOI: 10.2105/AJPH.2012.301182. View

Dobson S, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M . Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013; 309(17):1793-802. DOI: 10.1001/jama.2013.1625. View

Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen K, Kjaer S . Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013; 40(2):130-5. DOI: 10.1097/OLQ.0b013e31827bd66b. View

Anic G, Lee J, Stockwell H, Rollison D, Wu Y, Papenfuss M . Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. J Infect Dis. 2011; 204(12):1886-92. PMC: 3209812. DOI: 10.1093/infdis/jir652. View

Drolet M, Benard E, Boily M, Ali H, Baandrup L, Bauer H . Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5):565-80. PMC: 5144106. DOI: 10.1016/S1473-3099(14)71073-4. View

10.

Malagon T, Drolet M, Boily M, Franco E, Jit M, Brisson J . Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(10):781-9. DOI: 10.1016/S1473-3099(12)70187-1. View

11.

. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017; 35(43):5753-5755. DOI: 10.1016/j.vaccine.2017.05.069. View

12.

Guerra F, Rosella L, Dunn S, Wilson S, Chen C, Deeks S . Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment. Vaccine. 2016; 34(39):4678-4683. DOI: 10.1016/j.vaccine.2016.08.020. View